GSK Wins Paxil Trademark Fight in India, But Its Bigger Test Is Still Ahead
The Bombay High Court ordered Shreya Life Sciences to remove its registration of the Paxil trademark, siding with Glaxo Group Limited, part of GSK. The court found Shreya had not used the mark since registering it in 2005. GSK’s ADRs fell 1.2% to $51.01 in early New York trading. Investors remain focused on GSK’s vaccine and HIV businesses rather than the trademark ruling.